HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Petra Roll Selected Research

Rituximab (Mabthera)

5/2015Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis.
11/2012Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
6/2012Rituximab therapy leads to reduced imprints of receptor revision in immunoglobulin κ and λ light chains.
8/2009Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment.
2/2009Sustained Remission After Combination Therapy with Rituximab and Etanercept in Two Patients with Rheumatoid Arthritis After TNF Failure: Case Report.
12/2008Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab.
6/2008Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
1/2008Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
8/2006Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Petra Roll Research Topics

Disease

11Rheumatoid Arthritis
05/2015 - 08/2006
2Infections
06/2012 - 02/2009
1Graft vs Host Disease (Graft-Versus-Host Disease)
12/2015
1Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
11/2012
1Vasculitis (Vasculitides)
11/2012
1Measles
06/2012
1Mumps
06/2012
1Rubella (German Measles)
06/2012
1Tetanus
06/2012
1Diphtheria
06/2012
1Necrosis
08/2011
1Chronic Bronchitis
02/2009
1Pneumonia (Pneumonitis)
02/2009
1Rheumatic Diseases (Rheumatism)
06/2008

Drug/Important Bio-Agent (IBA)

9Rituximab (Mabthera)FDA Link
05/2015 - 08/2006
2tocilizumab (atlizumab)FDA Link
08/2011 - 05/2011
2Interleukin-6 (Interleukin 6)IBA
08/2011 - 05/2011
2AntibodiesIBA
01/2008 - 08/2006
1Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA
12/2015
1Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
03/2015
1Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
11/2012
1Biological ProductsIBA
06/2012
1Hepatitis B AntigensIBA
06/2012
1Immunoglobulins (Immunoglobulin)IBA
08/2011
1Etanercept (Enbrel)FDA Link
02/2009
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2009
1Tumor Necrosis Factor InhibitorsIBA
02/2009
1Anti-Bacterial Agents (Antibiotics)IBA
02/2009

Therapy/Procedure

4Therapeutics
11/2012 - 06/2008
1Hematopoietic Stem Cell Transplantation
12/2015